Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab Biosimilar (Oddifact SAS), 英夫利西单抗生物类似药(Oddifact SAS), INF2405 + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Behcet Syndrome | Preclinical | United States | 19 Nov 2025 | |
| Pyoderma Gangrenosum | Preclinical | United States | 09 Nov 2025 | |
| Mucocutaneous Lymph Node Syndrome | Preclinical | United States | 26 Jul 2024 |






